Illumina logged a -5.0% change during today's afternoon session, and is now trading at a price of $95.12 per share. On average, analysts give it a target price of $135.78.
Illumina, Inc. develops, manufactures, and markets life science tools and integrated systems for large-scale analysis of genetic variation and function. The large-cap company is based in the United States.
What to Consider if You Are Thinking of Buying Illumina:
Illumina has moved -58.0% over the last year.
ILMN has a forward P/E ratio of 99.1 based on its EPS guidance of 0.96.
Over the last 5 years, earnings per share (EPS) have been growing at a compounded average rate of -14.6%.
The company has a price to earnings growth (PEG) ratio of -23.46.
Its Price to Book (P/B) ratio is 2.55
Illumina Has None
|Date Reported||Cash Flow from Operations ($ k)||Capital expenditures ($ k)||Free Cash Flow ($ k)||YoY Growth (%)|